首页> 外文期刊>Oxidative Medicine and Cellular Longevity >Pretreatment with Roxadustat (FG-4592) Attenuates Folic Acid-Induced Kidney Injury through Antiferroptosis via Akt/GSK-3β/Nrf2 Pathway
【24h】

Pretreatment with Roxadustat (FG-4592) Attenuates Folic Acid-Induced Kidney Injury through Antiferroptosis via Akt/GSK-3β/Nrf2 Pathway

机译:通过AKT / GSK-3β/ NRF2途径通过防冻率衰减roxadustat(FG-4592)衰减叶酸诱导的肾损伤

获取原文
           

摘要

Folic acid- (FA-) induced kidney injury is characterized by the tubule damage due to the disturbance of the antioxidant system and subsequent interstitial fibrosis. FG-4592 is an inhibitor of prolyl hydroxylase of hypoxia-inducible factor (HIF), an antioxidant factor. The present study investigated the protective role of FG-4592 pretreatment at the early stage of the kidney injury and long-term impact on the progression of renal fibrosis. FG-4592 was administrated two days before FA injection in mice. On the second day after FA injection, the mice with FG-4592 pretreatment showed an improved renal function, compared with those without FG-4592 pretreatment, indicated by biochemical and histological parameters; meanwhile, the cellular content of iron, malondialdehyde, and 4-hydroxynonenal histologically decreased, implying the suppression of iron accumulation and lipid peroxidation. Simultaneously, upregulation of HIF-1α was found, along with Nrf2 activation, which was reflected by increased nuclear translocation and high-expression of downstream proteins, including heme-oxygenase1, glutathione peroxidase4, and cystine/glutamate transporter, as well as ferroportin. Correspondingly, the elevated levels of antioxidative enzymes and glutathione, as well as reduced iron accumulation, were observed, suggesting a lower risk of occurrence of ferroptosis with FG-4592 pretreatment. This was confirmed by reversed pathological parameters and improved renal function in FA-treated mice with the administration of ferrostatin-1, a specific ferroptosis inhibitor. Furthermore, a signal pathway study indicated that Nrf2 activation was associated with increased phosphorylation of Akt and GSK-3β, verified by the use of an inhibitor of the PI3K that phosphorylates Akt. Moreover, FG-4592 pretreatment also decreased macrophage infiltration and expression of inflammatory factors TNF-α and IL-1β. On the 14th day after FA injection, FG-4592 pretreatment decreased collagen deposition and expression of fibrosis biomarkers. These findings suggest that the protective role of FG-4592 pretreatment is achieved mainly by decreasing ferroptosis at the early stage of FA-induced kidney injury via Akt/GSK-3β-mediated Nrf2 activation, which retards the fibrosis progression.
机译:叶酸 - (FA-)诱导的肾损伤是由于抗氧化系统的干扰和随后的间质纤维化引起的小管损伤。 FG-4592是缺氧诱导因子(HIF)的脯氨酰羟化酶的抑制剂,抗氧化因子。本研究调查了FG-4592预处理在肾损伤早期的预处理的保护作用和对肾纤维化进展的长期影响。 FG-4592在小鼠的Fa注射前两天受到施用。在FA注射后的第二天,具有FG-4592预处理的小鼠显示出改善的肾功能,与没有FG-4592预处理的预处理相比,由生物化学和组织学参数表示;同时,铁,丙二醛和4-羟基的细胞含量减少,暗示了抑制铁积累和脂质过氧化。同时,发现HIF-1α的上调以及NRF2活化,其通过增加核转位数和下游蛋白质的高表达,包括血红素 - 氧合酶1,谷胱甘肽过氧化物酶,以及氰基/谷氨酸转运蛋白,以及脱盐素。相应地,观察到抗氧化酶和谷胱甘肽水平升高,以及减少的铁积累,表明FG-4592预处理的脱裂病变的发生风险较低。通过逆转的病理参数证实,并通过施用Ferrostatin-1,特定的裂解蛋白抑制剂,改善了FA治疗小鼠中的肾功能。此外,信号途径研究表明,NRF2活化与AKT和GSK-3β的磷酸化增加有关,通过使用磷酸化AKT的PI3K的抑制剂来验证。此外,FG-4592预处理还会降低巨噬细胞浸润和炎症因子TNF-α和IL-1β的表达。在Fa注射后的第14天,FG-4592预处理降低了胶原沉积和纤维化生物标志物的表达。这些发现表明FG-4592预处理的保护作用主要通过AKT / GSK-3β介导的NRF2活化在FA诱导的肾损伤早期降低的裂解元件来实现,这延缓了纤维化进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号